Transcrito

SonALAsense: Developing a Safe and Effective Noninvasive Treatment for Cancer.

5 de oct. de 2023 · 48m 55s
SonALAsense: Developing a Safe and Effective Noninvasive Treatment for Cancer.
Descripción

In a new episode of https://www.spreaker.com/user/7078249/tob-itunes-full-show-sonalasense-sdt, Peter Hofland talks with Ely Benaim, MD, the Chief Medical Officer and Executive Vice President Development at SonALAsense and Mark De Souza, Ph.D, President...

mostra más
In a new episode of The Onco’Zine Brief, Peter Hofland talks with Ely Benaim, MD, the Chief Medical Officer and Executive Vice President Development at SonALAsense and Mark De Souza, Ph.D, President and Chief Executive Officer of SonALAsense.

SonALAsense was founded to create hope in the face of despair with Sonodynamic Therapy (SDT), a non-invasive therapy option using SONALA-001 in combination with Insightec’s MR-guided focused ultrasound (MRgFUS) to treat and eradicate deadly cancers like High-Grade Gliomas (HGG) that typically require debilitating brain surgery that often leads to tumor recurrence.

SonALAsense’s SDT uses SONALA-001, a proprietary formulation of aminolevulinic acid (ALA), to disrupt heme metabolism in tumor cells, increasing production of protoporphyrin, a heme precursor. From there, energy from focused ultrasound excites protoporphyrin molecules, which produce reactive oxygen species that destroy cancer cells.

Recently, Hasan Syed, MD, at Children’s National Hospital published a peer-reviewed paper on the first DIPG patient treated with SONALA-001 in the Journal of Neuro-Oncology; a major milestone for this deadly and understudied childhood disease. [1]

Hofland, Benaim and De Souza talk about new technologies in the treatment of difficult to treat cancers.

Reference
[1] Syed HR, Kilburn L, Fonseca A, Nazarian J, Oluigbo C, Myseros JS, Packer RJ, Keating RF. First-in-human sonodynamic therapy with ALA for pediatric diffuse intrinsic pontine glioma: a phase 1/2 study using low-intensity focused ultrasound : Technical communication. J Neurooncol. 2023 Apr;162(2):449-451. doi: 10.1007/s11060-023-04269-8. Epub 2023 Apr 12. PMID: 37046110.

About The Onco'Zine Brief
The Onco'Zine Brief is distributed in the United States via PRX (Public Radio Exchange). In the United Kingdom and Europe, the program is distributed via UK Health Radio (UKHR). And the program can be downloaded via most podcasts and streaming media services, including iTunes, Spotify, TuneIn, and iHeart Radio.

For more information about The Onco'Zine Brief or how to sponsor or support this public radio broadcast and podcast, visit to download our Media Kit, visit our Patreon page, or contact the sales team.

To sign up for The Onco'Zine Newsletter (open for residents of the United States only), text the word CANCER to 66866.

The Onco’Zine Brief is made possible, in part, by Java Original Coffee and Roastmasterz by Java Original Coffee.
mostra menos
Información
Autor Peter Hofland
Organización Peter Hofland
Página web -
Etiquetas

Parece que no tienes ningún episodio activo

Echa un ojo al catálogo de Spreaker para descubrir nuevos contenidos.

Actual

Portada del podcast

Parece que no tienes ningún episodio en cola

Echa un ojo al catálogo de Spreaker para descubrir nuevos contenidos.

Siguiente

Portada del episodio Portada del episodio

Cuánto silencio hay aquí...

¡Es hora de descubrir nuevos episodios!

Descubre
Tu librería
Busca